Abstract
Treatment outcomes of acute leukemia (AL) have not improved over the past several decades and relapse rates remain high despite the availability of aggressive therapies. Conventional relapsed leukemia treatment includes second allogeneic hematopoietic stem cell transplantation (allo-HSCT) and donor lymphocyte infusion (DLI), which in most cases mediate, at best, a modest graft-versus-leukemia effect, although their clinical efficacy is still limited. Although allo-HSCT following myeloablative conditioning is a curative treatment option for younger patients with acute myeloid leukemia (AML) in a first complete remission (CR), allo-HSCT as a clinical treatment is usually limited because of treatment-related toxicity. The overall DLI remission rate is only 15%–42% and 2-year overall survival (OS) is approximately 15%–20%, with a high (40%–60%) incidence of DLI-related graft-versus-host disease (GVHD). Therefore, development of new, targeted treatment strategies for relapsed and refractory AL patients is ongoing. Adoptive transfer of T cells with genetically engineered chimeric antigen receptors (CARs) is an encouraging approach for treating hematological malignancies. These T cells are capable of selectively recognizing tumor-associated antigens and may overcome many limitations of conventional therapies, inducing remission in patients with chemotherapy-refractory or relapsed AL. In this review, we aimed to highlight the current understanding of this promising treatment modality, discussing its adverse effects and efficacy.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Appelbaum, F.R., Gundacker, H., and Head, D.R. (2006). Age and acute myeloid leukemia. Blood 107, 3481–3485.
Biffi, A, Bartolomae, C.C, and Cesana, D. (2011). Lentiviral vector common integration sites in preclinical models and a clinical trial reflect a benign integration bias and not oncogenic selection. Blood 117, 5332–5339.
Brenner, M.K. (2013). CAR-T cells for acute myeloid leukemia: the LeY of the land. Mol Ther 21, 1983–1984.
Brentjens, R.J, Santos, E, and Nikhamin, Y. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13, 5426–5435.
Brentjens, R.J, Riviè re, I., Park, J.H., Davila, M.L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S, Borquez-Ojeda, O., Olszewska, M.,Bernal,Y., Pegram, H., Przybylowski, M., Hollyman, D., Usachenko, Y., Pirraglia, D., Hosey, J., Santos, E., Halton, E., Maslak, P., Scheinberg, D., Jurcic, J., Heaney, M., Heller, G., Frattini, M., and Sadelain, M. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817–4828.
Davila, M.L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S.S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., and Shinglot, H. (2014). Efficacy and toxicity management of 19-28z CAR-T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 19, 224.
Dotti, G., Gottschalk, S., Savoldo, B., and Brenner, M.K. (2014). Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 257, 107–126.
Eshhar, Z., Waks, T., Gross, G., and Schindler, D.G. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90, 720–724.
Fielding, A.K., Richards, S.M., Chopra, R., Lazarus, H.M., Litzow, M.R., Buck, G., Durrant I.J., Luger, S.M., Marks, D.I., Franklin, I.M., McMillan, A.K., Tallman, M.S., and Rowe, J.M. (2007). Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL), an MRC UKALL12/ECOG 2993 study. Blood 1093, 944–950.
Gibson, B.E., Wheatley, K., Hann, I.M., Stevens, R.F., Webb, D., Hills, R.K., De Graaf, S.S., and Harrison, C.J. (2005). reatment strategy and long-term results in paediatric patients treated in consecu tive UKAML trials. Leukemia19, 2130–2138.
Gill, S., Tasian, S.K., Ruella, M., Shestova, O., Li, Y., Porter, D.L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S.A., June, C.H., and Kalos, M. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood 123, 2343–2354.
Gokbuget, N., Stanze, D., Beck, J., Diedrich, H., and Horst, H.A. (2012). Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 10, 2032–2041.
Goker H., Malkan U.Y., Demiroglu H., and Buyukasik Y. (2016). Chimeric antigen receptor T cell treatment in hematologic malignancies. Transfus Apher Sci 54, 35–40.
Creutzig, U., Büchner, T., Sauerland, M.C., Zimmermann, M., Reinhardt, D., Döhner, H., and Schlenk, R.F. (2008). Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A. Cancer 112, 562–571.
Gross, G., Waks, T., and Eshhar, Z. (1989). Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86, 10024–10028.
Grupp, S.A., Kalos, M., Barrett, D., Aplenc, R., Porter, D.L., Rheingold, S.R., Teachey, D.T., Chew, A., Hauck, B., Wright, J.F., Milone, M.C., Levine, B.L., and June, C.H. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368, 1509–1518.
Kaspers, G.J., and Creutzig, U. (2006). Pediatric acute myeloid leukemia: international progress and future directions. Leukemia 19, 2025–2029.
Lange, B.J., Smith, F.O., Feusner, J., Barnard, D.R., Dinndorf, P., Feig, S., Heerema, N.A., Arndt, C., Arceci, R.J., Seibel, N., Weiman, M., Dusenbery, K., Shannon, K., Luna-Fineman, S., Gerbing, R.B., and Alonzo, T.A. (2008). Outcomes in CCG-2961, a children’s oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children’s oncology group. Blood 111, 1044–1053.
Lee, D.W., Kochenderfer, J.N., Stetler-Stevenson, M., Cui, Y.K., Delbrook, C., Feldman, S.A., Fry, T.J., Orentas, R., Sabatino, M., Shah N.N., Steinberg, S.M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S.A., Wayne, A.S., and Mackall, C.L. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet 385, 517–528.
Moritz, D., Wels, W., Mattern, J., and Groner, B. (1994). Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-ressing tumor cells. Proc Natl Acad Sci USA 91, 4318–4322.
Jena, B., Dotti, G., and Cooper, L.J. (2010). Redirecting T-cell specificity by introducing a tumor specific chimeric antigen receptor. Blood 116, 1035–1044.
Jensen, M.C., Popplewell, L., Cooper, L.J., DiGiusto, D., Kalos, M., Ostberg, J.R., and Forman, S.J. (2010). Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 16, 1245–1256.
Jin, Z., Maiti, S., Huls, H., Singh, H., Olivares, S., Mátés, L., Izsvák, Z., Ivics, Z., Lee, D.A., Champlin, R.E., and Cooper, L.J. (2011). The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18, 849–856.
Kershaw, M.H, Westwood, J.A., Parker, L.L., Wang, G., Eshhar, Z., and Mavroukakis, S.A. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12, 6106–6115.
Kochenderfer, J.N., Dudley, M.E., Feldman, S.A., Wilson, W.H., Spaner, D.E., and Maric, I. (2012). B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 119, 2709–2720.
Mardiros, A., Dos Santos, C., McDonald, T., Brown, C.E., Wang, X., Budde, L.E., Hoffman, L., Aguilar, B., Chang, W.C., Bretzlaff, W., Chang, B., Jonnalagadda, M., Starr, R., Ostberg, J.R., Jensen, M.C., Bhatia, R., and Forman, S.J. (2013). T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions andantitumor effects against human acute myeloid leukemia. Blood 122, 3138–3148.
Maude, S.L., Frey, N., Shaw, P.A., Aplenc, R., Barrett, D.M., Bunin, N.J., Chew, A., Gonzalez, V.E., Zheng, Z., Lacey, S.F., Mahnke, Y.D., Melenhorst, J.J., Rheingold, S.R., Shen, A., Teachey, D.T., Levine, B.L., June, C.H., Porter, D.L., and Grupp, S.A. (2014). Chimeric antigen ceptor T cells for sustained remissions in leukemia. N Engl J Med 371, 1507–1517.
Maus, M.V., Grupp, S.A., Porter, D.L., and June, C.H. (2014). Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood 123, 2625–2635.
Ritchie, D.S., Neeson, P.J., Khot, A., Peinert, S., and Tai T. (2013). Persistence and efficacy of second generation CAR-T cell against the LeY antigen in acute myeloid leukemia. Mol Ther 21, 2122–2129.
Scholler, J., Brady, T.L., and Binder-Scholl, G. (2012). Decade-long safety and function of retroviralmodified chimeric antigen receptor T cells. SciTransl Med 4, 132ra153.
Teng, M.W., Kershaw, M.H., Moeller, M., Smyth, M.J., and Darcy, P.K. (2004). Immunotherapy of cancer using systemically delivered genemodified human T lymphocytes. Hum Gene Ther 15, 699–708.
Till, B.G., Jensen, M.C., Wang, J., Chen, E.Y., Wood, B.L., Greisman, H.A., Qian, X., James, S.E., Raubitschek, A., Forman, S.J., Gopal, A.K., Pagel, J.M., Lindgren, C.G., Greenberg, P.D., Riddell, S.R., and Press, O.W. (2008) Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261–2271.
Wen, Y.J., Min, R., Tricot, G., Barlogie, B., and Yi, Q. (2002). Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 99, 3280–3285.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Ding, G., Chen, H. Adoptive transfer of T cells transduced with a chimeric antigen receptor to treat relapsed or refractory acute leukemia: efficacy and feasibility of immunotherapy approaches. Sci. China Life Sci. 59, 673–677 (2016). https://doi.org/10.1007/s11427-016-0017-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-016-0017-3